TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Company Overview - TG Therapeutics, Inc. is a fully integrated, commercial stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases [3] - The company has received FDA approval for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) [3] - BRIUMVI has also been approved by the European Commission and the Medicines and Healthcare Products Regulatory Agency for treating adult patients with RMS who have active disease [3] Upcoming Events - Michael S. Weiss, the Chairman and CEO of TG Therapeutics, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference from June 10-13, 2024 [2] - The fireside chat is scheduled for June 11, 2024, at 1:20 PM ET [2] - A live webcast of the fireside chat will be available on the company's website [4]